Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ra Medical Systems Reports 2021 Fourth Quarter and Full Year Financial Results

RMED

Conference call begins at 4:30 p.m. Eastern time today

Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on developing its excimer laser system to treat vascular disease, reports financial results for the three months and full year ended December 31, 2021 and provides a business update.

Recent Operational Highlights

  • Filed 510(k) application with the FDA for our next-generation DABRA catheter that incorporates a braided overjacket designed to improve robustness and includes data supporting a six-month shelf life
  • Enrolled 13 subjects in the company’s atherectomy pivotal clinical study since mid-November 2021, for a total of 98 subjects enrolled, and received approval from the FDA to increase study enrollment from 100 to 125 subjects
  • Preliminarily demonstrated the ability of our technology to generate shockwaves that can fracture arterial medial calcium, a procedure commonly referred to as intravascular lithotripsy, in benchtop models

“I am pleased with the progress we are making on all key initiatives,” said Will McGuire, Ra Medical Systems CEO. “First, filing the 510(k) for our next-generation catheter that incorporates the braided overjacket is a significant engineering and regulatory stepping-stone toward our flagship commercial DABRA catheter, which will be a guidewire-compatible design. Second, I’m encouraged that we continued to advance subject enrollment in our clinical study during the pandemic. And third, we believe that fracturing medial calcium in benchtop models validated our system’s potential to be competitive in the emerging intravascular lithotripsy market.

“Finally, I want to commend the Ra Medical team for executing during these unprecedented times and for the support of our physician partners who have helped us achieve our milestones to date,” added Mr. McGuire.

Fourth Quarter Financial Highlights

Net revenue for the fourth quarter of 2021 consisted of product sales of $5,000, compared with no net revenue for the fourth quarter of 2020.

Total cost of revenue for the fourth quarter of 2021 was $0.3 million, compared with $0.4 million for the fourth quarter of 2020.

Selling, general and administrative expenses for the fourth quarter of 2021 were $4.2 million, which included $0.2 million in stock-based compensation, compared with $6.4 million for the fourth quarter of 2020, which included $0.8 million in stock-based compensation. Research and development expenses for the fourth quarter of 2021 were $3.7 million, which included $0.1 million in stock-based compensation, compared with $3.4 million for the fourth quarter of 2020, which included $0.1 million in stock-based compensation.

The net operating loss for the fourth quarter of 2021 was $8.3 million, or $1.23 per share on 6.7 million weighted-average shares outstanding, compared with a loss for the fourth quarter of 2020 of $10.2 million, or $3.54 per share on 2.9 million weighted-average shares outstanding.

Adjusted EBITDA for the fourth quarter of 2021 was negative $7.8 million, compared with negative $8.8 million for the fourth quarter of 2020. Adjusted EBITDA is a non-GAAP measure presented as loss from continuing operations before depreciation and amortization expense, interest income, interest expense, income taxes, stock-based compensation, gain and loss from sales and disposals of property and equipment, and gain on extinguishment of the Paycheck Protection Program (PPP) promissory note. For additional information regarding the non-GAAP financial measures discussed in this news release, please see "Non-GAAP Reconciliations" below.

2021 Financial Highlights

Continuing Operations

Net revenue for 2021 consisted of product sales of $22,000. This compares with net revenue for 2020 of $0.3 million which consisted primarily of product sales.

Total cost of revenue for 2021 was $1.6 million, compared with $2.2 million for 2020.

Selling, general and administrative expenses for 2021 were $15.5 million, which included $1.8 million in stock-based compensation, compared with $24.5 million for 2020, which included $3.2 million in stock-based compensation. Research and development expenses for 2021 were $12.3 million, which included $0.3 million in stock-based compensation, compared with $9.0 million for 2020, which included $0.4 million in stock-based compensation.

Net operating loss for 2021 was $27.3 million, or $5.39 per share on 5.1 million weighted-average shares outstanding, compared with a loss for 2020 of $35.3 million, or $20.79 per share on 1.7 million weighted-average shares outstanding.

Adjusted EBITDA for 2021 was negative $26.5 million, compared with negative $29.7 million for 2020. For additional information regarding the non-GAAP financial measures discussed in this news release, please see "Non-GAAP Reconciliations" below.

Ra Medical reported cash and cash equivalents of $15.0 million as of December 31, 2021.

2021 Financial Highlights

Discontinued Operations

Net revenue for 2021 was $2.6 million, which consisted of product sales of $0.9 million and service and other revenue of $1.7 million. This compares with net revenue for 2020 of $4.1 million, which consisted of product sales of $1.1 million and service and other revenue of $3.0 million.

Total cost of revenue for 2021 was $2.3 million, compared with $3.3 million for 2020.

Selling, general and administrative expenses for 2021 were $1.1 million, compared with $1.4 million for 2020. Research and development expenses for 2021 were $0.4 million, compared with $0.1 million for 2020.

The loss from discontinued operations for 2021 was $1.3 million, compared with a loss for 2020 of $0.7 million.

The gain on sale of the dermatology business for 2021 was $3.5 million.

The income/loss from discontinued operations, including the gain on sale of the dermatology business, for 2021 was income of $2.2 million, or $0.43 per share on 5.1 million weighted-average shares outstanding, compared with a loss for 2020 of $0.7 million, or $0.43 per share on 1.7 million weighted-average shares outstanding.

Conference Call and Webcast

Ra Medical will hold a conference call and audio webcast to discuss this announcement and answer questions at 4:30 p.m. Eastern time today. The conference call dial-in numbers are 866-777-2509 for domestic callers and 412-317-5413 for international callers, and the passcode is 9255498. A live webcast of the call will be available on the Investor Relations section of www.ramed.com.

A recording of the call will be available for 48 hours beginning approximately two hours after the completion of the call by dialing 877-344-7529 for domestic callers, 855-669-9658 for Canadian callers or 412-317-0088 for international callers. Please use the passcode 9255498. A webcast replay will be available on the Investor Relations section of www.ramed.com for 30 days, beginning approximately two hours after the completion of the call.

Non-GAAP Financial Measures

Ra Medical has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the three-month periods and full years ended December 31, 2021 and 2020. EBITDA and Adjusted EBITDA are performance measures that provide supplemental information management believes is useful to analysts and investors to evaluate Ra Medical’s ongoing results of operations, when considered alongside other GAAP measures. These measures are intended to aid investors in better understanding Ra Medical’s current financial performance and prospects for the future as seen through management. Management uses non-GAAP measures to compare the company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. Management believes that these non-GAAP financial measures facilitate comparisons with Ra Medical’s historical results and with the results of peer companies who present similar measures (although other companies may define non-GAAP measures differently than we define them, even when similar terms are used to identify such measures). Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Ra Medical encourages investors to carefully consider its results under U.S. GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between U.S. GAAP and non-GAAP operating results are presented in the accompanying tables of this news release.

Investors are encouraged to review the related U.S. GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business. Ra Medical defines EBITDA as our GAAP loss from continuing operations as adjusted to exclude depreciation and amortization, interest income, interest expense and income tax expense. Ra Medical defines Adjusted EBITDA as EBITDA adjusted to exclude stock-based compensation, gain on extinguishment of PPP promissory note and gain/loss on sales and disposals of property and equipment.

About Ra Medical Systems

Ra Medical Systems manufactures the DABRA excimer laser and catheters for the treatment of vascular diseases. DABRA has been cleared by the FDA for crossing chronic total occlusions in patients with symptomatic infrainguinal lower extremity vascular disease and has an intended use for ablating a channel in occlusive peripheral vascular disease. In addition, DABRA has been granted CE mark clearance for the endovascular treatment of infrainguinal arteries via atherectomy and for crossing total occlusions. DABRA breaks down plaque to proteins, lipids and other chemical compounds, eliminating blockages by essentially dissolving them without generating potentially harmful particulates. DABRA excimer lasers and catheters are manufactured in a 32,000 square-foot facility located in Carlsbad, CA. The vertically integrated facility is ISO 13485 certified and is licensed by the State of California to manufacture sterile, single-use catheters in clean room environments.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Ra Medical’s future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern Ra Medical’s future expectations, strategy, plans or intentions. Forward-looking statements in this press release include, but are not limited to, statements regarding Ra Medical’s business strategy, the potential of the DABRA system for new applications of use, the market opportunity and growth of current and potential markets and its ability to continue to manage expenses and cash burn rate at sustainable levels. Ra Medical’s expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, challenges inherent in developing, manufacturing, launching, marketing, and selling new products or new applications of use; risks associated with acceptance of DABRA devices for current and potential applications of use and procedures performed using such devices by physicians, payors, and other third parties; development and acceptance of new products, product enhancements or applications of use; clinical and statistical verification of the benefits achieved via the use of Ra Medical’s products; the results from our clinical trials, which may not support intended indications or may require Ra Medical to conduct additional clinical trials or modify ongoing clinical trials; challenges related to commencement, patient enrollment, completion, an analysis of clinical trials; Ra Medical’s ability to manage operating expenses; Ra Medical’s ability to recruit and retain management and key personnel; Ra Medical’s need to comply with complex and evolving laws and regulations; intense and increasing competition and consolidation in Ra Medical’s industry; the impact of rapid technological change; adverse outcome of regulatory inspections; impacts from public health crises, such as the Covid-19 pandemic, geopolitical conflicts, such as Russia’s invasion of Ukraine and related sanctions against Russia and Belarus, or natural disasters; and the other risks and uncertainties described in Ra Medical’s news releases and filings with the Securities and Exchange Commission. Information on these and additional risks, uncertainties, and other information affecting Ra Medical’s business and operating results is contained in Ra Medical’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 and in its other filings with the Securities and Exchange Commission. Additional information is also set forth in Ra Medical’s Annual Report on Form 10-K for the year ended December 31, 2021 to be filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Ra Medical as of the date hereof, and Ra Medical disclaims any obligation to update any forward-looking statements, except as required by law.

Ra Medical investors and others should note that we announce material information to the public about the company through a variety of means, including our website (www.ramed.com), our investor relations website (https://ir.ramed.com/), press releases, SEC filings and public conference calls in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

Ra Medical Systems, Inc.

Condensed Balance Sheets

(Unaudited)

(in thousands)

December 31,
2021

December 31,
2020

ASSETS

Current Assets

Cash and cash equivalents

$

15,045

$

23,906

Accounts receivable, net

21

24

Inventories

986

877

Prepaid expenses and other current assets

1,037

1,100

Current assets of discontinued operations

1,713

Total current assets

17,089

27,620

Property and equipment, net

1,809

2,527

Operating lease right-of-use-assets

2,110

2,484

Other long-term assets

36

45

Long-term assets of discontinued operations

762

TOTAL ASSETS

$

21,044

$

33,438

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities

Accounts payable

$

988

$

471

Accrued expenses

4,119

4,147

Current portion of operating lease liabilities

283

356

Current portion of PPP promissory note

421

Current portion of equipment financing

265

Current liabilities of discontinued operations

2,102

Total current liabilities

5,390

7,762

Operating lease liabilities

1,981

2,264

PPP promissory note

1,579

Long-term liabilities of discontinued operations

686

Total liabilities

7,371

12,291

Total stockholders’ equity

13,673

21,147

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

$

21,044

$

33,438

Ra Medical Systems, Inc.

Condensed Statements of Operations

(Unaudited)

(in thousands, except per share data)

Three Months Ended
December 31,

Year Ended
December 31,

2021

2020

2021

2020

Net revenues

Product sales

$

5

$

$

22

$

254

Service and other

5

Total net revenues

5

22

259

Cost of revenues

Product sales

156

238

832

1,369

Service and other

191

188

728

803

Total cost of revenues

347

426

1,560

2,172

Gross loss

(342

)

(426

)

(1,538

)

(1,913

)

Operating expenses

Selling, general and administrative

4,190

6,379

15,475

24,533

Research and development

3,732

3,421

12,253

8,955

Total operating expenses

7,922

9,800

27,728

33,488

Operating loss

(8,264

)

(10,226

)

(29,266

)

(35,401

)

Other income (expense), net

(19

)

(9

)

2,009

88

Loss from continuing operations before income taxes

(8,283

)

(10,235

)

(27,257

)

(35,313

)

Income taxes

4

7

4

7

Loss from continuing operations

(8,287

)

(10,242

)

(27,261

)

(35,320

)

Discontinued operations

(Loss) income from discontinued operations (including gain on sale of $3,500 in 2021) before income taxes

(226

)

2,191

(725

)

Income taxes

(Loss) Income from discontinued operations

(226

)

2,191

(725

)

Net loss

$

(8,287

)

$

(10,468

)

$

(25,070

)

$

(36,045

)

Net (loss) income per share, basic and diluted

Continuing operations

$

(1.23

)

$

(3.54

)

$

(5.39

)

$

(20.79

)

Discontinued operations

(0.08

)

0.43

(0.43

)

Total net loss per share, basic and diluted

$

(1.23

)

$

(3.62

)

$

(4.96

)

$

(21.22

)

Basic and diluted weighted average common shares outstanding

6,742

2,895

5,055

1,699

Ra Medical Systems, Inc.
Non-GAAP Reconciliations
(Unaudited)
(in thousands)
Three Months Ended
December 31,
Year Ended
December 31,

2021

2020

2021

2020

Statement of Operations Data:
Loss from continuing operations

$

(8,287

)

$

(10,242

)

$

(27,261

)

$

(35,320

)

Depreciation and amortization

315

417

1,289

1,947

Interest income

(1

)

(1

)

(3

)

(129

)

Interest expense

10

12

41

Income tax expense

4

7

4

7

EBITDA

(7,969

)

(9,809

)

(25,959

)

(33,454

)

Stock-based compensation

252

941

2,054

3,682

Gain on extinguishment of PPP promissory note

(2,023

)

(Gain) Loss on sales and disposals of property and equipment

(61

)

99

(550

)

99

Adjusted EBITDA

$

(7,778

)

$

(8,769

)

$

(26,478

)

$

(29,673

)

Tags: